DrugPatentWatch Database Preview
Details for Patent: 10,065,947
Email this page to a colleague
» See Plans and PricingWhich drugs does patent 10,065,947 protect, and when does it expire?
Patent 10,065,947 protects SIVEXTRO and is included in two NDAs.
This patent has forty patent family members in twenty-eight countries.
Summary for Patent: 10,065,947
| Title: | Forms of R)-3-(4-(2-(2-methyltetrazol-5-yl)pyridin-5-yl)-3-fluorophenyl)-5- -hydroxymethyl oxazolidin-2-one dihydrogen phosphate |
| Abstract: | A crystalline form of crystalline (R)-3-(4-(2-(2-methyltetrazol-5-yl)-pyridin-5-yl)-3-fluorophenyl)-5-hydro- xymethyl oxazolidin-2-one dihydrogen phosphate, methods of making the crystalline form and pharmaceutical compositions comprising the crystalline form are useful antibiotics. Further, the derivatives of the present invention may exert potent antibacterial activity versus various human and animal pathogens, including Gram-positive bacteria such as Staphylococi, Enterococci and Streptococi, anaerobic microorganisms such as Bacteroides and Clostridia, and acid-resistant microorganisms such as Mycobacterium tuberculosis and Mycobacterium avium. Accordingly, the compositions comprising the crystalline form may be used in antibiotics. |
| Inventor(s): | Reichenbacher; Katharina (Riehen, CH), Duguid; Robert J. (Glenmont, NY), Ware; Jacqueline A. (Virginia Beach, VA), Phillipson; Douglas (Del Mar, CA) |
| Assignee: | Merck Sharp & Dohme Corp. (Rahway, NJ) |
| Application Number: | 15/970,492 |
|
Patent Claim Types: see list of patent claims | Composition; Compound; |
Drugs Protected by US Patent 10,065,947
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cubist Pharms Llc | SIVEXTRO | tedizolid phosphate | POWDER;INTRAVENOUS | 205436-001 | Jun 20, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||||
| Cubist Pharms Llc | SIVEXTRO | tedizolid phosphate | TABLET;ORAL | 205435-001 | Jun 20, 2014 | RX | Yes | Yes | Start Trial | Start Trial | Y | Start Trial | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,065,947
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| African Regional IP Organization (ARIPO) | 2987 | Start Trial | |||
| Australia | 2010210627 | Start Trial | |||
| Brazil | PI1008829 | Start Trial | |||
| Canada | 2751392 | Start Trial | |||
| Chile | 2011001855 | Start Trial | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
